AbCellera Biologics Inc. 8-K

What Happened AbCellera Biologics (ABCL) filed an 8‑K on January 14, 2026 disclosing that it issued a press release (dated January 12, 2026) announcing the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. The company also posted an updated corporate presentation to its investor website on January 14, 2026. The filing was signed by CEO Carl L. G. Hansen, Ph.D.

Key Details

• First patients dosed in the Phase 2 portion of the ongoing Phase 1/2 trial for ABCL635 (announced Jan 12, 2026).
• AbCellera furnished the press release as Exhibit 99.1 and the updated corporate presentation (dated Jan 14, 2026) as Exhibit 99.2 in the 8‑K.
• The updated presentation was posted to https://investors.abcellera.com on January 14, 2026.
• The disclosure was made under Regulation FD and reported in Item 7.01 of the Form 8‑K; exhibits are listed under Item 9.01.

Why It Matters Advancing from Phase 1 to dosing in the Phase 2 portion of a trial is a concrete clinical development milestone for ABCL635 and indicates the program is progressing through its planned clinical stages. For investors, this is a factual update on development progress and provides new company‑issued materials (press release and presentation) that may contain additional program or pipeline context.